Replay CEO Lachlan MacKinnon (L) and president Adrian Woolfson

Mak­er of new gene ther­a­py vec­tor launch­es its sec­ond com­pa­ny, look­ing to ze­ro in on rare skin con­di­tions

The hub-and-spoke biotech Re­play, which came on­to the scene with $55 mil­lion in seed cap­i­tal and a vi­sion to launch four com­pa­nies around its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.